News
A group from Nagoya University in Japan has developed a simple, accurate, and sensitive method for measuring polysialic acid, ...
Sanofi (NASDAQ: SNY) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On June 25, Sanofi (NASDAQ:SNY) ...
A team of physicians recently reported the successful treatment of refractory autoimmune neuropathies through the infusion of ...
The companies place the partnership’s value at up to $1.5 billion, including an undisclosed up-front payment in the ...
The US Food and Drug Administration (FDA) has approved Japanese pharma major Takeda’s Gammagard Liquid ERC [immune globulin ...
Paris: Sanofi has received orphan drug designation from the Ministry of Health, Labour and Welfare (MHLW) in Japan for ...
Japanese MHLW grants orphan drug designation to Sanofi’s riliprubart for chronic inflammatory demyelinating polyneuropathy: Paris Tuesday, July 1, 2025, 09:00 Hrs [IST] The Mini ...
Explore the latest on VYVGART HYTRULO's FDA safety signal and transition challenges. Learn why argenx's balanced risks keep ...
Results of two phase 2 studies suggest efgartigimod could be a potential treatment for myositis and Sjögren disease in ...
Sanofi (ENXTPA:SAN) recently received orphan drug designation from Japan's Ministry of Health for riliprubart, aimed at treating chronic inflammatory demyelinating polyneuropathy. This underscores the ...
FDA raised safety concerns for Vyvgart Hytrulo in CIDP, while Argenx moves ARGX-119 into late-stage trials for rare ...
(NASDAQ:ARGX) is down ~7% in Monday trading after the U.S. FDA issued an alert on a potential signal of serious risks associated with Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase). The agency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results